Arcellx, Inc.
ACLX
Rangering i aksjer
#2784
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Aksjekurs
$115.07
Sist synkronisert: 2026-05-15
Markedsverdi
$6.73B
Endring (1 dag)
0.00%
Endring (1 år)
32.28%
Land
US
Handel Arcellx, Inc. (ACLX)
Kategori
Healthcare
EPS for Arcellx, Inc. (ACLX)
EPS per December 2025 TTM: $-4.07
Ifølge de siste økonomiske rapportene og aksjekursen til Arcellx, Inc. er selskapets nåværende EPS (TTM) $-4.07. Ved slutten av 2023 hadde selskapet en EPS på $-1.47, en nedgang sammenlignet med EPS-en i 2022 som var $-4.28.
EPS-historikk for Arcellx, Inc. fra 2018 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $-4.07 | 103.50% |
| 2024 | $-2.00 | 36.05% |
| 2023 | $-1.47 | -65.65% |
| 2022 | $-4.28 | 120.62% |
| 2021 | $-1.94 | 31.97% |
| 2020 | $-1.47 | 182.69% |
| 2019 | $-0.52 | -98.96% |
| 2018 | $-50.17 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $17.32 | -525.55% |
US
|
|
| $-7.98 | 96.07% |
US
|
|
| $-5.29 | 29.98% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -781.57% |
NL
|
